ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
44 announcements with these filters
Advanced Enzyme Technologies announced an open market buyback of up to 13.94 lakh shares at a maximum price of ₹500 per share.
Advanced Enzyme Technologies is investing ₹2 Crore in its wholly-owned subsidiary, Advanced Nutrazyme Private Limited. This capital infusion supports the subsidiary's ongoing business operations.
Advanced Enzyme Technologies Limited will acquire the remaining 4.28% stake in JC Biotech Private Limited for ₹7.98 Crore, making it a wholly-owned subsidiary.
Advanced Enzyme Technologies Limited's board approved a buyback of up to 1.39 million shares worth ₹69.7 Crore via the open market to optimize capital.
Advanced Enzyme reported Q1 FY27 revenue of ₹1,898 mn, up 2% YoY, despite a 10% EBITDA decline. Segment performance was mixed, with specialized manufacturing and bio-processing showing strong growth.
Advanced Enzyme Technologies announced its Q1 FY27 consolidated financial highlights. Consolidated revenue from operations stood at ₹189.8 Crore for the quarter.
Advanced Enzyme Technologies Ltd reported revenue from operations of ₹189.8 Cr (+2.1% YoY) and net profit of ₹38.6 Cr (-4.5% YoY) for Q1 FY27.
Advanced Enzyme Technologies Ltd scheduled a board meeting for August 08, 2026, to consider Q1 FY27 financial results and a proposal for a share buyback.
Advanced Enzyme Technologies Ltd held its 37th Annual General Meeting on July 31, 2026, to discuss and vote on various ordinary and special business resolutions.
Advanced Enzyme Technologies filed its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI regulations.
Board recommended Rs.1.35/share dividend and director reappointments for AGM. Related party transactions with subsidiary and relative also approved.
Advanced Enzyme Technologies Ltd filed its Integrated Annual Report for FY 2025-26. The report highlights ₹7,458 million revenue and 1,736 million PAT.
Advanced Enzyme Technologies filed its BRSR for FY2025-26, detailing operations and CSR. The report covers employee data, subsidiaries, and sustainability risks without financial surprises.
Advanced Enzyme Technologies Ltd. is convening its 37th AGM on July 31, 2026. The agenda includes financial statements, dividend declaration, and director appointments.